Shenghe Pharmaceutical

Nanjing Shenghe Pharmaceutical is a leading Chinese pharmaceutical company dedicated to the research, development, and commercialization of innovative medicines across multiple therapeutic areas. Founded in 1996 and headquartered in Nanjing, the company has built an integrated value chain encompassing R&D centers, GMP-certified manufacturing bases, and a robust domestic marketing network. Shenghe is best known for its success in the anti-infective space with Morinidazole, an innovative nitroimidazole antibiotic, and its expansion into oncology with the launch of Limertinib, a third-generation EGFR inhibitor. The company maintains a significant focus on high-prevalence diseases in China, including cancer, infectious diseases, and digestive system disorders. With a strong emphasis on independent innovation, Shenghe continues to advance a diverse pipeline of small molecule candidates through clinical development.